This is why Esperion Therapeutics Inc. (ESPR) Stock is one of the options for the Longer run

Esperion Therapeutics Inc. [ESPR] stock prices are up 2.29% to $2.68 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The ESPR shares have gain 27.01% over the last week, with a monthly amount glided 4.28%, and seem to be holding up well over a long-time horizon.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

On 26, March 2024, Esperion to Participate in 23rd Annual Needham Virtual Healthcare Conference. In a post published today on Yahoo Finance, Esperion (NASDAQ: ESPR) today announced its participation in the 23rd Annual Needham Virtual Healthcare Conference. Sheldon Koenig, President and CEO, will participate in a fireside chat on Tuesday, April 9, 2024, at 12:45 PM ET. The Esperion management team will also host investor meetings that same day.

From an analyst’s perspective:

Esperion Therapeutics Inc. [NASDAQ: ESPR] stock has seen the most recent analyst activity on January 03, 2024, when BofA Securities downgraded its rating to a Neutral. On August 01, 2023, upgrade upgraded it’s rating to Market Perform. BofA Securities upgraded its rating to a Buy and increased its price target to $4 on June 15, 2023. Northland Capital downgraded its rating to a Under Perform but $1 remained the price target by the analyst firm on March 16, 2023. BofA Securities downgraded its rating to Underperform for this stock on March 16, 2023, and downed its price target to $1.50. In a note dated March 07, 2023, Credit Suisse upgraded an Neutral rating on this stock and boosted its target price from $6.50 to $7.

The stock price of Esperion Therapeutics Inc. [ESPR] has been fluctuating between $0.70 and $3.34 over the past year. Currently, Wall Street analysts expect the stock to reach $16 within the next 12 months. Esperion Therapeutics Inc. [NASDAQ: ESPR] shares were valued at $2.68 at the most recent close of the market. An investor can expect a potential return of 497.01% based on the average ESPR price forecast.

Analyzing the ESPR fundamentals

The Esperion Therapeutics Inc. [NASDAQ:ESPR] reported sales of 116.33M for trailing twelve months, representing a surge of 71.38%. Gross Profit Margin for this corporation currently stands at 0.63% with Operating Profit Margin at -1.34%, Pretax Profit Margin comes in at -1.8%, and Net Profit Margin reading is -2.04%. To continue investigating profitability, this company’s Return on Assets is posted at -1.15, Equity is 0.36 and Total Capital is -3.14. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-1.18.

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.55 points at the first support level, and at 2.41 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.81, and for the 2nd resistance point, it is at 2.93.

Esperion Therapeutics Inc. [ESPR] reported earnings per share of -$0.5 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.48/share, meaning a difference of -$0.02 and a surprise factor of -4.20%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$0.37 per share as compared to estimates of -$0.43 per share, a difference of $0.06 representing a surprise of 14.00%.

Ratios To Look Out For

It’s worth pointing out that Esperion Therapeutics Inc. [NASDAQ:ESPR]’s Current Ratio is 1.29. Further, the Quick Ratio stands at 0.87, while the Cash Ratio is 0.53. Considering the valuation of this stock, the price to sales ratio is 3.93.

Transactions by insiders

Recent insider trading involved Warren Eric, Chief Commercial Officer, that happened on Sep 20 ’23 when 742.0 shares were sold. Chief Commercial Officer, Warren Eric completed a deal on Aug 18 ’23 to sell 243.0 shares. Meanwhile, Chief Commercial Officer Warren Eric sold 106.0 shares on Jul 19 ’23.

Related Posts